1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Can COMPASS Bring Psilocybin’s ‘Magic’ To Depression?

COMPASS Pathways Hopes To Market its Psilocybin Capsule By 2025

 
• By Sten Stovall

COMPASS is testing a synthetic form of psilocybin, the active “magic mushroom” ingredient, in long-term depression patients, and thinks the capsule can be approved by 2025, its co-founder tells Scrip.

Mushrooms_Brain
UK-Based group’s psilocybin therapy has fast track status • Source: Shutterstock

COMPASS Pathways believes it has found a viable, mind-altering therapy for treating long-term depression: a synthetic form of psilocybin now in Phase IIb trials which, if successful, could surmount current legal barriers and stigma associated with psychedelic substances, the company’s co-founder and chief innovation officer told Scrip.

A big step towards that goal was achieved this year in a placebo-controlled Phase I study evaluating COMP360 (psilocybin) in healthy volunteers, and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

In Brief: Ferrer Signs Deal For Prilenia’s Pridopidine In Europe

 
• By Sushmita Panda

The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.

More from Therapy Areas